Cathinone: An investigation of several N-alkyl and methylenedioxy-substituted analogs

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 4, 1997, Pages 1109-1116

  Dal Cason, Terry A ^a   Young, Richard ^b   Glennon, Richard A ^b  

^a Drug Enforcement Administration   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Amphetamine; Cathinone; Designer drugs; MDA; MDMA; Methamphetamine; Methcathinone

Indexed keywords

2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CATHINONE; CATHINONE DERIVATIVE; DESIGNER DRUG; DIMETAMFETAMINE; METHCATHINONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DISCRIMINATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; REINFORCEMENT; STIMULUS GENERALIZATION; STRUCTURE ACTIVITY RELATION;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ALKALOIDS; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DISCRIMINATION (PSYCHOLOGY); MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGENTS; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031415190     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00323-7     Document Type: Article

References (41)

1. Ashgar K., De Souza E. Pharmacology and toxicology of amphetamine and related designer drugs, NIDA Research Monograph 94. 1989;U.S. Government Printing Office, Washington, DC.
2. Bockmuhl, M.; Ehrhart, G.: 1-(3′,4′-Dioxyalkylenephenyl)-2-aminoalkanol. U.S. Patent 1,964,973, July 3; 1934.
3. Bonner R. C. Schedules of controlled substances. Temporary placement of methcathinone into Schedule I. Fed. Reg. 57:1992;9080-9081(March 16) and 18824-18825 (May 1).
4. Boyer J. H., Straw D. Azidocarbonyl compounds. The pyrolysis of azidocarbonyl compounds. J. Am. Chem. Soc. 75:1952;1642-1644.
5. Calkins R. F., Aktan G. B., Hussain K. L. Methcathinone. The next illicit stimulant epidemic? J. Psychoactive Drugs. 27:1995;277-285.
6. Emerson T. S., Cisek J. E. Methcathinone. A Russian designer amphetamine infiltrates the rural midwest Ann. Emerg. Med. 22:1993;1897-1903.
7. Finney D. Probit analysis. 1952;Cambridge University Press, London.
8. Glennon R. A. Discriminative stimulus properties of phenylisopropylamine derivatives. Drug Alcohol Depend. 17:1986;119-134.
9. Glennon R. A. Psychoactive phenylisopropylamines. Meltzer H. Psychopharmacology, third generation of progress. 1987;1627-1634 Raven Press, New York.
10. Glennon R. A. Stimulus properties of hallucinogenic phenylalkylamines and related designer drugs. Formulation of structure-activity relationships NIDA Res. Monogr. 94:1989;43-67.
11. Glennon R. A. Phenylalkylamine stimulants, hallucinogens, and designer drugs. NIDA Res. Monogr. 105:1991;154-160.
12. Glennon R. A., Higgs R. Investigation of MDMA-related agents in rats trained to discriminate MDMA from saline. Pharmacol. Biochem. Behav. 43:1992;759-763.
13. Glennon R. A., Showalter D. The effect of cathinone and several related derivatives on locomotor activity. Res. Commun. Subst. Abuse. 2:1981;186-192.
14. Glennon R. A., Young R. Further investigation of the discriminative stimulus properties of MDA. Pharmacol. Biochem. Behav. 20:1984;501-505.
15. Glennon R. A., Schechter M. D., Rosecrans J. A. Discriminative stimulus properties of S(-)- and R(+)-cathinone, (+)-cathine, and several structural modifications. Pharmacol. Biochem. Behav. 21:1984;1-3.
16. Glennon R. A., Little J. A., Rosecrans J. A., Yousif M. The effect of MDMA ("Ecstasy") on schedule-controlled responding in mice. Pharmacol. Biochem. Behav. 26:1987;425-426.
17. Glennon R. A., Yousif M., Patrick G. Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol. Biochem. Behav. 29:1988;443-449.
18. Glennon R. A., Young R., Martin B. R., Dal Cason T. A. Methcathinone ("CAT"). An enantiomeric potency comparison Pharmacol. Biochem. Behav. 50:1995;601-606.
19. Glennon R. A., Yousif M., Naiman N., Kalix P. Methcathinone. A new and potent amphetamine-like agent Pharmacol. Biochem. Behav. 26:1987;547-551.
20. Hartung W. H. Palladium catalysts. II. The effect of hydrogen chloride in the hydrogenation of isonitrosoketones. J. Am. Chem. Soc. 53:1931;2248-2253.
21. Hartung W. H., Crossley F. Isonitrosopropiophenone. Blatt A. H. Organic synthesis, collective vol. 1943;363-364 John Wiley & Sons, II. New York.
22. Hartung W. H., Munch J. C. Amino alcohols. I. Phenylpropanolamine and para-tolylpropanolamine. J. Am. Chem. Soc. 51:1929;2262-2266.
23. Hyde J. F., Browning E., Adams R. Synthetic homologs of ephedrine. J. Am. Chem. Soc. 50:1928;2287-2292.
24. Iwamoto H. K., Hartung W. H. Amino alcohols. XIV. Methoxyl derivatives of phenyl propanolamine and 3,5-dihydroxyphenylpropanolamine. J. Org. Chem. 9:1944;513-517.
25. Kaminski B. J., Griffiths R. R. Intravenous self-injection of methcathinone in the baboon. Pharmacol. Biochem. Behav. 47:1994;77-86.
26. Kamlet, J.: Preparation of alpha-alkylamino-acylophenones. U.S. Patent 2,155,194, April 18, 1939.
27. Katz J. L., Ricaurte G. A., Witkin J. M. Reinforcing effects of N,N-dimethylamphetamine in squirrel monkeys. Psychopharmacology (Berlin). 107:1992;315-318.
28. Metamfepramone, Monograph 5828. Merck Index, 11th ed. S. Budavari, ed., Rahway, NJ: Merck & Co.
29. Nichols D. E., Oberlender R. Structure-activity relationships of MDMA-like substances. Ashgar K., De Souza E. Pharmacology and toxicology of amphetamine and related designer drugs. 1989;1-29 U.S. Government Printing Office, Washington, DC.
30. Savenko, V. G.; Semkin, E. P.; Sorokin, V. I.; Kazankov, S. P.: Expert examination of narcotic substances obtained from ephedrine. Document published by the All-Union Scientific Research Institute of the U.S.S.R. Ministry of Interior, Moscow; 1989.
31. Schorno X., Steinegger E. CNS-Active phenylpropylamines of catha edulis FORSK. (Celastraceae) of Kenyan origin. Experientia. 35:1979;572-574.
32. Takamatsu H. Studies on optically active phenylpropanolamine derivatives I. Preparation of optically active α-aminopropiophenones by asymmetric transformation. J. Pharmacol. Soc. Jpn. 76:1956;1219-1222.
33. United Nations Bulletin on Narcotics (Special Issue devoted to Catha edulis), 32 (#3); 1980.
34. van der Schoot J. B., Ariens E., Van Rossum J. M., Hurkmans J. A. Th. Phenylisopropylamine derivatives, structure and action. Arzneimittelforschung. 12:1962;902-907.
35. Witkin J. M., Ricaurte G. A., Katz J. L. Behavioral effects of N-methylamphetamine and N,N-dimethylamphetamine in rats and squirrel monkeys. J. Pharmacol. Exp. Ther. 253:1990;466-474.
36. Woolverton W. L., Shybut G., Johanson C. E. Structure-activity relationships of some d-N-alkylated amphetamines. Pharmacol. Biochem. Behav. 13:1980;869-876.
37. Young R., Glennon R. A. Discriminative stimulus properties of amphetamine and structurally related phenylalkylamines. Med. Res. Rev. 6:1986;99-130.
38. Young R., Glennon R. A. Cocaine-stimulus generalization to two new designer drugs. Methcathinone and 4-methylaminorex Pharmacol. Biochem. Behav. 45:1993;229-231.
39. Young R., Glennon R. A. A three-lever operant procedure differentiates the stimulus effects of R(-)MDA from S(+)MDA. J. Pharmacol. Exp. Ther. 276:1996;594-601.
40. Young R., Darmani N. A., Elder E. L., Dumas D., Glennon R. A. Clobenzorex. Evidence for amphetamine-like behavioral actions Pharmacol. Biochem. Behav. 56:1997;311-316.
41. Zhingel K. Y., Dovensky W, Crossman A., Allen A. Ephedrone. 2-methylamino-1-propan-1-one (Jeff) J. Forensic Sci. 36:1991;915-920.